Campbell Rogers Sells 9,219 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 9,219 shares of Heartflow stock in a transaction on Monday, August 17th. The stock was sold at an average price of $41.23, for a total value of $380,099.37. Following the transaction, the insider directly owned 86,459 shares of the company’s stock, valued at approximately $3,564,704.57. This represents a 9.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Heartflow Stock Performance

Heartflow stock opened at $46.80 on Friday. The firm has a market capitalization of $4.07 billion and a price-to-earnings ratio of -25.57. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $47.95. The stock’s fifty day moving average is $30.33 and its two-hundred day moving average is $28.17.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The firm had revenue of $64.08 million for the quarter. Heartflow’s revenue for the quarter was up 47.7% on a year-over-year basis. As a group, sell-side analysts forecast that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Institutional Trading of Heartflow

Hedge funds have recently bought and sold shares of the company. TrueMark Investments LLC raised its holdings in Heartflow by 1.4% in the 1st quarter. TrueMark Investments LLC now owns 26,885 shares of the company’s stock valued at $654,000 after acquiring an additional 379 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Heartflow in the fourth quarter valued at $27,000. Strs Ohio increased its stake in Heartflow by 35.3% in the first quarter. Strs Ohio now owns 4,600 shares of the company’s stock valued at $112,000 after purchasing an additional 1,200 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Heartflow in the fourth quarter valued at $45,000. Finally, Legal & General Group Plc purchased a new position in Heartflow during the third quarter worth about $59,000.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HTFL. Morgan Stanley raised their price objective on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Freedom Capital raised Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. Wells Fargo & Company boosted their price target on Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Robert W. Baird set a $45.00 price objective on Heartflow in a research report on Friday, August 14th. Finally, Canaccord Genuity Group increased their price objective on Heartflow from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.43.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.